Antengene Corporation Ltd. has announced a new global clinical collaboration with MSD to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy, in patients with advanced solid tumors. This collaboration aims to explore the efficacy of ATG-022, which has demonstrated significant activity across varying levels of Claudin 18.2 expression in gastric cancer, positioning it as a potential treatment option for a broad patient demographic. The announcement was made on May 20, 2025, highlighting Antengene's commitment to developing innovative cancer therapies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。